Brachytherapy and Radionuclide Therapy: Strontium-89 for Bone Metastases
A 65-year-old man with metastatic castration-resistant prostate cancer has multiple painful osteoblastic bone metastases in the spine and pelvis. He has been on docetaxel and enzalutamide but has progression. His pain is poorly controlled with opioids, and he has a history of spinal cord compression at T8 treated with surgery and radiation 6 months ago. His platelet count is 80,000/µL, and his absolute neutrophil count is 1,500/µL. He is being considered for strontium-89 (Sr-89) therapy. He lives alone and has limited social support.
1. Is this patient a candidate for Sr-89? Discuss the indications, contraindications, and expected outcomes.
Read the worked answer
Sr-89 is a beta-emitting radiopharmaceutical indicated for palliation of painful osteoblastic bone metastases. This patient has multiple painful osteoblastic lesions, which is the primary indication. However, his platelet count of 80,000/µL is below the typical threshold for Sr-89 (often >100,000/µL), and his ANC of 1,500/µL is borderline. Sr-89 can cause myelosuppression, particularly thrombocytopenia, which may be prolonged. Given his prior spinal cord compression and surgery, there is a risk of cord compression if the tumor swells; however, Sr-89 is not typically associated with tumor swelling. The main contraindications include severe myelosuppression, disseminated intravascular coagulation, and pregnancy. His limited social support is a concern because he may need help with transportation and monitoring for side effects. Expected outcomes: about 60-80% of patients experience pain relief within 1-2 weeks, lasting up to 3-6 months. A transient increase in pain (flare) can occur. He should be counseled on potential myelosuppression and the need for blood count monitoring. Given his low platelets, alternative therapies such as external beam radiation to dominant painful sites or analgesics should be considered. If Sr-89 is pursued, dose reduction or alternative agent (e.g., samarium-153) might be considered, but both have similar myelosuppressive effects.
2. What patient education and safety precautions should be provided?
Read the worked answer
Patient education for Sr-89 includes: (1) explaining the purpose (pain relief, not cure), (2) expected timeline for effect (1-2 weeks, may take up to 4 weeks), (3) potential side effects: myelosuppression (low blood counts, increased infection risk, bleeding), pain flare, and rare allergic reactions. (4) Safety precautions: Sr-89 is excreted renally, so patients should use appropriate hygiene, flush toilet twice, and wash hands. Because it is a beta emitter, external radiation exposure is minimal; no major restrictions for contact with others, but avoiding prolonged close contact with pregnant women and children for a few days is prudent. (5) Monitoring: complete blood counts weekly for 4-6 weeks. (6) Given his limited social support, arrange for a home health aide or social work consult to assist with transportation and symptom management. (7) Encourage hydration to facilitate excretion. (8) Discuss with his oncologist the timing of subsequent chemotherapy, as Sr-89 may increase myelosuppression.